BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30987989)

  • 1. Cost-effectiveness of faecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease.
    Zhang W; Wong CH; Chavannes M; Mohammadi T; Rosenfeld G
    BMJ Open; 2019 Apr; 9(4):e027043. PubMed ID: 30987989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
    Yang Z; Clark N; Park KT
    Clin Gastroenterol Hepatol; 2014 Feb; 12(2):253-62.e2. PubMed ID: 23883663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
    Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care.
    Conroy S; Hale MF; Cross SS; Swallow K; Sidhu RH; Sargur R; Lobo AJ
    J Clin Pathol; 2018 Apr; 71(4):316-322. PubMed ID: 28844038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study.
    Motaganahalli S; Beswick L; Con D; van Langenberg DR
    Intern Med J; 2019 Jan; 49(1):94-100. PubMed ID: 29962008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms.
    Mowat C; Digby J; Strachan JA; Wilson R; Carey FA; Fraser CG; Steele RJ
    Gut; 2016 Sep; 65(9):1463-9. PubMed ID: 26294695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta-analysis.
    An YK; Prince D; Gardiner F; Neeman T; Linedale EC; Andrews JM; Connor S; Begun J
    Med J Aust; 2019 Nov; 211(10):461-467. PubMed ID: 31680263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
    Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
    Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders.
    Lozoya Angulo ME; de Las Heras Gómez I; Martinez Villanueva M; Noguera Velasco JA; Avilés Plaza F
    Gastroenterol Hepatol; 2017 Mar; 40(3):125-131. PubMed ID: 27260632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a 'real-world' view.
    McFarlane M; Chambers S; Malik A; Lee B; Sung E; Nwokolo C; Waugh N; Arasaradnam R
    BMJ Open; 2016 Jun; 6(6):e011041. PubMed ID: 27266773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study.
    Högberg C; Karling P; Rutegård J; Lilja M
    Scand J Gastroenterol; 2017 Jan; 52(1):69-75. PubMed ID: 27623716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease.
    Bressler B; Panaccione R; Fedorak RN; Seidman EG
    Can J Gastroenterol Hepatol; 2015 Oct; 29(7):369-72. PubMed ID: 26125109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to use faecal calprotectin in management of paediatric inflammatory bowel disease.
    Saha A; Tighe MP; Batra A
    Arch Dis Child Educ Pract Ed; 2016 Jun; 101(3):124-8. PubMed ID: 26848103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years.
    Kennedy NA; Clark A; Walkden A; Chang JC; Fascí-Spurio F; Muscat M; Gordon BW; Kingstone K; Satsangi J; Arnott ID; Lees CW
    J Crohns Colitis; 2015 Jan; 9(1):41-9. PubMed ID: 25135754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of Fecal Calprotectin in Evaluation of Chronic Gastrointestinal Symptoms in Primary Care.
    Ramraj R; Garcia A; Mosen D; Waiwaiole L; Smith N
    Clin Pediatr (Phila); 2018 Aug; 57(9):1058-1063. PubMed ID: 29192504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients' perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey.
    Kalla R; Boyapati R; Vatn S; Hijos G; Crooks B; Moore GT; Hall V; Lipscomb G; Gomollón F; Jahnsen J; Singh S
    Scand J Gastroenterol; 2018 Dec; 53(12):1437-1442. PubMed ID: 30451040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.
    Ikhtaire S; Shajib MS; Reinisch W; Khan WI
    J Gastroenterol; 2016 May; 51(5):434-46. PubMed ID: 26897740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical usefulness of the faecal calprotectin test in suspected paediatric inflammatory bowel disease.
    Akobeng AK
    Acta Paediatr; 2018 Nov; 107(11):2019-2023. PubMed ID: 29706011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study.
    Kwapisz L; Mosli M; Chande N; Yan B; Beaton M; Micsko J; Mennill PW; Barnett W; Bax K; Ponich T; Howard J; Tirolese A; Lannigan R; Gregor J
    Saudi J Gastroenterol; 2015; 21(6):360-6. PubMed ID: 26655130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal calprotectin: current usage and perceived beneficial effects of third-party funding on rates of colonoscopy by Australian gastroenterologists.
    Elnawsra O; Fok I; Sparrow M; Gibson P; Andrews J; Connor S
    Intern Med J; 2016 May; 46(5):590-5. PubMed ID: 26946938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.